CN113801101A - AZD 9291-2-ketoglutarate and preparation method thereof - Google Patents
AZD 9291-2-ketoglutarate and preparation method thereof Download PDFInfo
- Publication number
- CN113801101A CN113801101A CN202010543540.XA CN202010543540A CN113801101A CN 113801101 A CN113801101 A CN 113801101A CN 202010543540 A CN202010543540 A CN 202010543540A CN 113801101 A CN113801101 A CN 113801101A
- Authority
- CN
- China
- Prior art keywords
- degrees
- azd
- ketoglutarate
- azd9291
- salt according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 239000013078 crystal Substances 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000005855 radiation Effects 0.000 claims abstract description 8
- 238000002441 X-ray diffraction Methods 0.000 claims abstract description 7
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 21
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 21
- 229960003278 osimertinib Drugs 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000009210 therapy by ultrasound Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 4
- 229910017488 Cu K Inorganic materials 0.000 claims description 3
- 229910017541 Cu-K Inorganic materials 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 229910002483 Cu Ka Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- FUKSNUHSJBTCFJ-UHFFFAOYSA-N osimertinib mesylate Chemical compound CS(O)(=O)=O.COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 FUKSNUHSJBTCFJ-UHFFFAOYSA-N 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102100025490 Slit homolog 1 protein Human genes 0.000 description 2
- 101710123186 Slit homolog 1 protein Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010071977 Anaplastic lymphoma kinase gene mutation Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102100037709 Desmocollin-3 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010071975 EGFR gene mutation Diseases 0.000 description 1
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 1
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 239000000174 gluconic acid Chemical class 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- -1 salts sulfate Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
The invention relates to the technical field of crystal form drug molecules, and particularly provides an AZD 9291-2-ketoglutarate, a preparation method and an application thereof, wherein the AZD 9291-2-ketoglutarate uses Cu-Kalpha radiation, and has characteristic peaks at 6.12 +/-0.2 degrees, 10.30 +/-0.2 degrees, 15.11 +/-0.2 degrees, 20.88 +/-0.2 degrees, 22.93 +/-0.2 degrees and 25.25 +/-0.2 degrees in an X-ray diffraction spectrogram expressed by 2 theta.
Description
Technical Field
The invention relates to the technical field of crystal form drug molecules, in particular to the technical field of AZD9291 crystal forms, and specifically relates to an AZD 9291-2-ketoglutarate and a preparation method and application thereof.
Background
AZD9291(Osimertinib), chemical name: n- [2- [ [2- (dimethylamino) ethyl ] (methyl) amino ] -4-methoxy-5- [ [4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl ] amino ] phenyl ] prop-2-enamide, english name: n- (2- { [2- (Dimethylamino) ethyl ] (methyl) amino } -4-methoxy-5- { [4- (1-methyl-1H)
-indol-3-yl)-2-pyrimidinyl]amino } phenyl) acrylamide. CAS number:1421373-65- 0the structural formula is shown as follows:
if the lung cancer patient has EGFR or ALK gene mutation, the targeted drug can obtain better survival benefit. However, the efficacy of these drugs is generally short-lived, and resistance occurs in months 9-11, which arises because cancer cells can evade the therapeutic activity of EGFR or ALK inhibitors by mutating and changing the growth pattern.
ADZ9291, developed by AstraZeneca (AstraZeneca), is a third generation oral, irreversible selective EGFR mutation inhibitor useful for activating and resistant mutant EGFR, i.e., 50% of acquired resistance to EGFR treatment for advanced non-small cell lung cancer patients is caused by the T790M mutation, and ADZ9291 can nullify this challenging mutation. ADZ9291 has better treatment effect on NSCLC patients with existing resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and T790M mutation.
Patent CN103702990A discloses the structure of ADZ9291 compound. Polymorphic forms of this compound and its mesylate salt are also disclosed in this patent, including form B of the ADZ9291 mesylate salt form A, ADZ9291 mesylate salt. Patent CN104961731A discloses ADZ9291 phosphate; patent CN106432231A discloses ADZ9291 pharmaceutically acceptable salts sulfate, p-toluenesulfonate, tartrate, acetate and citrate; patent CN107915725A patent discloses novel pharmaceutically acceptable salts of maleic acid, fumaric acid, gluconic acid, malonic acid, succinic acid and lactic acid.
The former company used the mesylate salt of AZD9291 for clinical studies. However, methanesulfonic acid is highly toxic and, in selective cases, unsuitable for pharmaceutical use. And the methanesulfonate has problems of high hygroscopicity and deliquescence due to high humidity. Therefore, it is necessary to develop other salts with high bioavailability, low toxicity and suitability for pharmaceutical use. Although the prior literature has disclosed numerous AZD9291 crystal forms, systematic studies on the crystal forms are still to be perfected.
Disclosure of Invention
In view of the defects of the prior art, the invention provides the AZD 9291-2-ketoglutarate and the preparation method thereof, and the crystal form prepared by the invention has good stability and high solubility and is beneficial to pharmacy.
The specific technical content of the invention is as follows:
the AZD 9291-2-ketoglutarate provided by the invention uses Cu-Kalpha radiation, and an X-ray diffraction spectrum expressed by 2 theta has characteristic peaks at 6.12 +/-0.2 degrees, 10.30 +/-0.2 degrees, 15.11 +/-0.2 degrees, 20.88 +/-0.2 degrees, 22.93 +/-0.2 degrees and 25.25 +/-0.2 degrees.
Preferably, the AZD 9291-2-ketoglutarate has an X-ray diffraction spectrum expressed in 2 theta using Cu-K alpha radiation with characteristic peaks at 6.12 +/-0.2 degrees, 9.81 +/-0.2 degrees, 10.30 +/-0.2 degrees, 11.30 +/-0.2 degrees, 14.12 +/-0.2 degrees, 15.11 +/-0.2 degrees, 19.66 +/-0.2 degrees, 20.31 +/-0.2 degrees, 20.88 +/-0.2 degrees, 22.93 +/-0.2 degrees, 25.25 +/-0.2 degrees, 25.32 +/-0.2 degrees.
Preferably, the AZD 9291-2-ketoglutarate salt has an X-ray diffraction pattern as shown in figure 1, using Cu-ka radiation.
Preferably, the AZD 9291-2-ketoglutarate has an endothermic peak detected by Differential Scanning Calorimetry (DSC), the starting point of which is 141.14 ℃ and the peak is 155.52 ℃. The AZD 9291-2-oxoglutarate salt presents a DSC/TGA pattern as shown in figure 4.
The invention provides a method for preparing the AZD 9291-2-ketoglutarate, which comprises the following steps:
adding AZD9291 and 2-ketoglutaric acid into an organic solvent, performing ultrasonic treatment until all the components are dissolved, filtering, placing the filtrate in an evaporator, standing at room temperature for natural volatilization, and filtering to obtain a light yellow blocky crystal; drying to obtain the product.
The mol ratio of the AZD9291 to the 2-ketoglutaric acid is 1: 1 to 2.
The mass-volume ratio of the AZD9291 to the organic solvent is 15-50: 1, wherein the mass is in mg and the volume is in ml.
The organic solvent is one or a combination of several of methanol, ethanol, acetone, acetonitrile or tetrahydrofuran.
The ultrasonic power of the ultrasonic instrument is 150-300W.
The room temperature is 10-30 ℃.
And standing for natural volatilization for 2-7 days.
The drying temperature is 40-70 ℃.
The drying time is 2-7 h.
Confirmation of Crystal Structure of AZD 9291-2-oxoglutarate
The X-ray crystal data of the invention is collected on a Japan science XtaLAB Synergy model instrument, the temperature is measured at 293(2) K, CuKa radiation is used, and data is collected in an omega scanning mode and Lp correction is carried out. Analyzing the structure by a direct method, finding out all non-hydrogen atoms by a difference Fourier method, obtaining all hydrogen atoms on carbon and nitrogen by theoretical hydrogenation, and refining the structure by a least square method.
The X-ray powder diffraction test instrument and the test conditions of the invention are as follows: PANALYTIC EMPyrean X-ray powder diffractometer; light source Cu target, flat sample stage, incident light path: BBHD, diffraction path: PIXCEL, voltage 45KV, current 40mA, divergence slit 1/4 degrees, anti-divergence slit 1 degree, cable-stayed slit 0.04rad degree, counting time of each step 0.5s, and scanning range 3-50 degrees.
The TGA/DSC thermal analysis tester and the test conditions in the invention are as follows: TGA/DSC thermogram METTLERTODO TGA/DSC3 +; dynamic temperature section: 30-300 ℃; heating rate: 10 ℃/min; segment gas N2(ii) a Gas flow rate: 50 mL/min; crucible: an aluminum crucible of 40. mu.l.
The crystallographic data obtained by testing and analyzing the AZD 9291-2-oxoglutarate prepared by the invention are (see Table 1): the crystallographic parameters are as follows: triclinic system, space group is P-1; the unit cell parameters are:
a is 95.8135(10) °, β is 103.3820(13) °, γ is 101.0568(12) °, unit cell volume
The ORTEP chart of AZD 9291-2-ketoglutarate salt of the present invention shows that one molecule of AZD9291 binds to one molecule of 2-ketoglutarate acid, as shown in FIG. 2.
TABLE 1 Main crystallographic data for AZD 9291-2-ketoglutarate
According to the crystallography data, the characteristic peaks in the X-ray powder diffraction pattern (Cu-K alpha) corresponding to the AZD 9291-2-ketoglutarate are shown in the attached figure 1 and the table 2 in detail.
TABLE 2AZD 9291-2-oxoglutarate major XRD peaks
AZD 9291-2-ketoglutarate prepared by the invention has an endothermic peak detected by differential scanning thermal analysis (DSC), the starting point of which is 141.14 ℃, and the peak value of which appears at 155.52 ℃. The AZD 9291-2-oxoglutarate salt presents a DSC/TGA pattern as shown in figure 4.
All AZD 9291-2-ketoglutarate samples prepared by the invention have the same crystallographic parameters, X-ray powder diffraction pattern and TGA/DSC thermogram.
The invention also provides a pharmaceutical composition which comprises the AZD 9291-2-oxoglutarate prepared as described above and contains other active ingredients and/or pharmaceutically acceptable auxiliary components that can be used in combination.
Preferably, the pharmaceutical composition can be prepared into spray, tablets, capsules, powder injections, liquid injections and the like by using standard or conventional technology.
The invention also provides application of the AZD 9291-2-ketoglutarate in preparing a medicament for treating lung cancer, in particular application in preparing a medicament for treating non-small cell lung cancer.
Compared with the prior art, the AZD 9291-2-ketoglutarate prepared by the invention has obviously improved solubility and good stability and is suitable for preparing medicaments.
Drawings
FIG. 1 is an X-ray powder diffraction pattern of AZD 9291-2-ketoglutarate salt;
FIG. 2 is an ORTEP diagram of AZD 9291-2-ketoglutarate salt;
FIG. 3 is a schematic representation of the stacking cell of AZD 9291-2-ketoglutarate;
FIG. 4 is a TGA/DSC thermogram of AZD 9291-2-ketoglutarate salt.
Detailed Description
The invention is further illustrated by the following examples, which should be properly understood: the examples of the present invention are intended to be illustrative only and not to be limiting, and therefore, the present invention is intended to be simply modified within the scope of the present invention as claimed.
Example 1
Adding 2.5g of AZD9291 and 1.2g of 2-ketoglutaric acid into 100mL of acetone, performing ultrasonic treatment by using a sonicator 200W until all the components are dissolved, filtering, placing the filtrate in an evaporator with a small-hole membrane seal, standing at 10 ℃ for natural volatilization for 5 days, filtering to obtain a light yellow block crystal, and drying in an oven at 50 ℃ for 2 hours to obtain AZD 9291-2-ketoglutarate with the yield of 95.61% and the purity of 99.98%.
Example 2
Adding 2.5g of AZD9291 and 1.32g of 2-ketoglutaric acid into 75mL of methanol, performing ultrasonic treatment by an ultrasonic instrument of 250W until the mixture is completely dissolved, filtering, placing the filtrate in an evaporator with a small-hole membrane seal, standing at 15 ℃ for natural volatilization for 4 days, filtering to obtain light yellow blocky crystals, drying in an oven at 60 ℃ for 5 hours to obtain AZD 9291-2-ketoglutarate, wherein the yield is 93.39%, and the purity is 99.97%.
Example 3
Adding 2.5g of AZD9291 and 0.85g of 2-ketoglutaric acid into a mixed solvent of 50mL of acetone and 75mL of methanol, performing ultrasonic treatment by using an ultrasonic instrument of 150W until the mixture is completely dissolved, filtering, placing the filtrate in an evaporator with a small-hole membrane seal, standing at 20 ℃ for natural volatilization for 6 days, filtering to obtain a light yellow blocky crystal, and drying in an oven at 42 ℃ for 4.5h to obtain AZD 9291-2-ketoglutarate with the yield of 90.54% and the purity of 99.96%.
Example 4
Adding 5.0g of AZD9291 and 3.0g of 2-ketoglutaric acid into 100mL of acetonitrile, performing ultrasonic treatment by a sonicator 300W until all the components are dissolved, filtering, placing the filtrate in an evaporator with a small-hole membrane seal, standing at 23 ℃ for natural volatilization for 7 days, filtering to obtain a light yellow block crystal, and drying in an oven at 70 ℃ for 7 hours to obtain AZD 9291-2-ketoglutarate with the yield of 88.07% and the purity of 99.96%.
Example 5
Adding 2.5g of AZD9291 and 0.73g of 2-ketoglutaric acid into 167mL of tetrahydrofuran, performing ultrasonic treatment by using an ultrasonic instrument 150W until the mixture is completely dissolved, filtering, placing the filtrate in an evaporator with a small-hole membrane seal, standing at 30 ℃ for natural volatilization for 2 days, filtering to obtain light yellow blocky crystals, drying in an oven at 40 ℃ for 2 hours to obtain AZD 9291-2-ketoglutarate, wherein the yield is 83.97%, and the purity is 99.95%.
Example 6
Adding 2.5g of AZD9291 and 1.8g of 2-ketoglutaric acid into a mixed solvent of 125mL of acetone and 75mL of acetonitrile, performing ultrasonic treatment by an ultrasonic instrument of 250W until the mixture is completely dissolved, filtering, placing the filtrate in an evaporator with a small-hole membrane seal, standing at 20 ℃ for natural volatilization, filtering to obtain a light yellow blocky crystal, drying in an oven at 55 ℃ for 3 hours to obtain AZD 9291-2-ketoglutarate, wherein the yield is 66.64%, and the purity is 99.95%.
Verification test
(1) Stability test
The stability test was performed on the AZD 9291-2-oxoglutarate prepared in examples 1-6 of the present invention. The specific stability test method is carried out according to the guidance method of stability investigation in the fourth part of the Chinese pharmacopoeia 2015 edition, the purity is detected by an HPLC method, and the specific test results are shown in Table 3.
TABLE 3 stability test results of AZD 9291-2-ketoglutarate crystal form under illumination, high temperature and high humidity conditions
As can be seen from Table 3, the purity of the AZD 9291-2-oxoglutarate prepared in the embodiments 1-6 of the present invention does not change significantly under the conditions of illumination, high temperature and high humidity, and it can be seen that the AZD 9291-2-oxoglutarate prepared in the present invention has good stability.
(2) Solubility test
A comparative study of the solubility of AZD 9291-2-ketoglutarate prepared according to the invention from example 1 and AZD9291 mesylate in the prior art form A, AZD9291 fumarate was carried out. The method comprises the following steps: respectively measuring 10ml of medium (water, 0.1mol/LHCl solution and phosphate buffer solution with pH of 6.8) into a penicillin bottle, adding excessive samples to be detected, sealing the penicillin bottle, placing the penicillin bottle in a constant-temperature water bath at 25 ℃, stirring for 1 hour, filtering through a 0.45-micron filter membrane, and taking filtrate; the absorbance was measured at a wavelength of 210nm, and the solubility was calculated by measuring the absorbance of a standard control.
TABLE 4 solubility of AZD 9291-2-oxoglutarate in different media (mg/ml)
From the test data, compared with AZD9291 mesylate crystal form A, AZD9291 fumarate in the prior art, the AZD 9291-2-ketoglutarate prepared in the embodiment 1 of the invention has obviously improved solubility in water and phosphoric acid media, which shows that the AZD 9291-2-ketoglutarate prepared in the invention has good solubility, and can be prepared into a pharmaceutical preparation to be beneficial to absorption by human bodies.
Through tests, the AZD 9291-2-ketoglutarate prepared in the embodiments 2-6 has similar solubility to the AZD 9291-2-ketoglutarate prepared in the embodiment 1, and compared with AZD9291 mesylate crystal form A, AZD9291 fumarate in the prior art, the solubility of the AZD 9291-2-ketoglutarate in water and a phosphoric acid medium is remarkably improved.
Claims (9)
1. AZD 9291-2-ketoglutarate, which is characterized in that: the AZD 9291-2-ketoglutarate uses Cu-K alpha radiation, and an X-ray diffraction spectrum expressed by 2 theta has characteristic peaks at 6.12 +/-0.2 degrees, 10.30 +/-0.2 degrees, 15.11 +/-0.2 degrees, 20.88 +/-0.2 degrees, 22.93 +/-0.2 degrees, and 25.25 +/-0.2 degrees.
2. AZD 9291-2-ketoglutarate salt according to claim 1, characterized in that: the AZD 9291-2-ketoglutarate uses Cu-Kalpha radiation, and has characteristic peaks at 6.12 +/-0.2 degrees, 9.81 +/-0.2 degrees, 10.30 +/-0.2 degrees, 11.30 +/-0.2 degrees, 14.12 +/-0.2 degrees, 15.11 +/-0.2 degrees, 19.66 +/-0.2 degrees, 20.31 +/-0.2 degrees, 20.88 +/-0.2 degrees, 22.93 +/-0.2 degrees, 25.25 +/-0.2 degrees and 25.32 +/-0.2 degrees in an X-ray diffraction spectrum expressed by 2 theta.
3. AZD 9291-2-ketoglutarate salt according to claim 1, characterized in that: the AZD 9291-2-ketoglutarate salt has an X-ray diffraction pattern shown in figure 1 by using Cu-Ka radiation.
4. A process for the preparation of AZD 9291-2-ketoglutarate salt according to claims 1 to 3, characterised in that it comprises the following steps:
adding AZD9291 and 2-ketoglutaric acid into an organic solvent, performing ultrasonic treatment until all the components are dissolved, filtering, placing the filtrate in an evaporator, standing at room temperature for natural volatilization, and filtering to obtain a light yellow blocky crystal; drying to obtain the product.
5. The method of claim 4, wherein: the mol ratio of the AZD9291 to the 2-ketoglutaric acid is 1: 1 to 2.
6. The method of claim 4, wherein: the mass-volume ratio of the AZD9291 to the organic solvent is 15-50: 1, wherein the mass is in mg and the volume is in ml.
7. The method of claim 4, wherein: the organic solvent is one or a combination of several of methanol, ethanol, acetone, acetonitrile or tetrahydrofuran.
8. A pharmaceutical composition comprising AZD 9291-2-oxoglutarate salt according to any one of claims 1 to 4, and further active ingredients and/or pharmaceutically acceptable auxiliary components which may be used in combination.
9. Use of an AZD9291-2 ketoglutarate salt according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of lung cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010543540.XA CN113801101A (en) | 2020-06-15 | 2020-06-15 | AZD 9291-2-ketoglutarate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010543540.XA CN113801101A (en) | 2020-06-15 | 2020-06-15 | AZD 9291-2-ketoglutarate and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113801101A true CN113801101A (en) | 2021-12-17 |
Family
ID=78944442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010543540.XA Pending CN113801101A (en) | 2020-06-15 | 2020-06-15 | AZD 9291-2-ketoglutarate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113801101A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103702990A (en) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| CN104961731A (en) * | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof |
| CN106432231A (en) * | 2016-09-09 | 2017-02-22 | 无锡佰翱得生物科学有限公司 | AZD 9291 pharmaceutical salt and crystal form and preparation method thereof |
| CN106674202A (en) * | 2015-11-05 | 2017-05-17 | 惠州信立泰药业有限公司 | Dimethyl sulfonate of compound A, crystal form of dimethyl sulfonate, and medicinal composition containing dimethyl sulfonate |
| CN107176954A (en) * | 2017-06-02 | 2017-09-19 | 无锡双良生物科技有限公司 | Pharmaceutical salts and its crystal formation, the preparation method and application of a kind of EGFR inhibitor |
| CN107915725A (en) * | 2017-10-20 | 2018-04-17 | 复旦大学 | Pharmaceutical salts of AZD9291 and preparation method thereof |
| CN110483486A (en) * | 2019-09-17 | 2019-11-22 | 鲁南制药集团股份有限公司 | A kind of western Tenylidone of Austria coughs up hydrochlorate crystal form and preparation method thereof |
-
2020
- 2020-06-15 CN CN202010543540.XA patent/CN113801101A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103702990A (en) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| CN104961731A (en) * | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof |
| CN106674202A (en) * | 2015-11-05 | 2017-05-17 | 惠州信立泰药业有限公司 | Dimethyl sulfonate of compound A, crystal form of dimethyl sulfonate, and medicinal composition containing dimethyl sulfonate |
| CN106432231A (en) * | 2016-09-09 | 2017-02-22 | 无锡佰翱得生物科学有限公司 | AZD 9291 pharmaceutical salt and crystal form and preparation method thereof |
| CN107176954A (en) * | 2017-06-02 | 2017-09-19 | 无锡双良生物科技有限公司 | Pharmaceutical salts and its crystal formation, the preparation method and application of a kind of EGFR inhibitor |
| CN107915725A (en) * | 2017-10-20 | 2018-04-17 | 复旦大学 | Pharmaceutical salts of AZD9291 and preparation method thereof |
| CN110483486A (en) * | 2019-09-17 | 2019-11-22 | 鲁南制药集团股份有限公司 | A kind of western Tenylidone of Austria coughs up hydrochlorate crystal form and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018275277B2 (en) | Pharmaceutically acceptable salt of EGFR inhibitor, crystal form thereof, preparation method therefor and application thereof | |
| TWI597277B (en) | Form i crystal of dimaleate salt of tyrosine kinase inhibitor and preparation method thereof | |
| WO2016124137A1 (en) | Phosphate of epidermal growth factor receptor inhibitor, crystalline form of phosphate, and preparation method | |
| CN110483486B (en) | Crystal form of oxtinib ketorolac and preparation method thereof | |
| CN112047892B (en) | Gefitinib and 3-hydroxybenzoic acid eutectic | |
| AU2015330554B2 (en) | Crystal form of bisulfate of JAK inhibitor and preparation method therefor | |
| CN112142679B (en) | Gefitinib and vanilloid eutectic methanol solvate and preparation method thereof | |
| US20140200232A1 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| CN112047893B (en) | Gefitinib and salicylic acid co-crystal | |
| AU2015342444B2 (en) | Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof | |
| US9957237B2 (en) | Crystal form of neptinib di-p-methylbenzenesulfonate, preparation method thereof, and pharmaceutical composition containing same | |
| CN114685455A (en) | AZD9291 crystalline solid | |
| CN113968845A (en) | AZD 9291-gallate and preparation method thereof | |
| CN114075169A (en) | Pharmaceutical cocrystal of oxitinib and preparation method thereof | |
| CN113801101A (en) | AZD 9291-2-ketoglutarate and preparation method thereof | |
| CN114075170A (en) | Oxitinib medicinal salt and preparation method thereof | |
| CN113929664A (en) | AZD9291-3, 5-pyridine dicarboxylic acid salt and preparation method thereof | |
| CN113929663A (en) | AZD 9291-2-indole formate and preparation method thereof | |
| CN109867669B (en) | Crystal form of pyrazolo [1,5-a ] pyridine compound, and pharmaceutical composition and application thereof | |
| CN109867671B (en) | Crystal form of pyrazolo [1,5-a ] pyridine compound, and pharmaceutical composition and application thereof | |
| CN113372331A (en) | Novel crystal form of oxitinib monohydrate | |
| CN114276350B (en) | Ketorolac and phenazine eutectic and preparation method thereof | |
| CN114105957A (en) | Oxitinib-terephthalic acid crystal and preparation method thereof | |
| CN114502550B (en) | Tegafur co-crystal | |
| WO2023093861A1 (en) | Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |